363 results · Page 1 of 15

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated AdultsCOVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumoniaRecruitingPhase 12026-10-09NCT07536308
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver diseaseRecruitingPhase 22026-10-09NCT07288138
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorderRecruitingPhase 32026-10-09NCT07198074
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesAlzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 32026-10-09NCT07177352
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerLocally Advanced Cervical Adenocarcinoma; Locally Advanced Cervical Adenosquamous Carcinoma; Locally Advanced Cervical Squamous Cell Carcinoma; Stage IIIA Cervical Cancer FIGO 2018; Stage IIIB Cervical Cancer FIGO 2018; Stage IIIC1 Cervical Cancer FIGO 2018; Stage IIIC2 Cervical Cancer FIGO 2018; Stage IVA Cervical Cancer FIGO 2018RecruitingPhase 32026-10-09NCT07061977
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorderRecruitingPhase 32026-10-09NCT06878261
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Diabetic Peripheral Neuropathic PainActive, not recruitingPhase 32026-10-09NCT06696443
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 2 / Phase 32026-10-09NCT06616584
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerAnatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast CarcinomaRecruitingPhase 32026-10-09NCT06058377
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)Alzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, amyloidosis, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyNot yet recruitingPhase 12026-10-08NCT07843459
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityBody Weight, Nutritional and Metabolic Diseases, Obesity, Abdominal, Overweight, Pathological Conditions, Signs and Symptoms, Prehypertension, Signs and Symptoms, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, prediabetes syndrome, vascular disorderRecruitingPhase 32026-10-08NCT07794579
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's DiseaseAlzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, amyloidosis, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 12026-10-08NCT07787169
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arthritic joint disease, arthropathy, musculoskeletal system disorder, nutritional disorder, obesity disorder, osteoarthritis, overnutrition, rheumatic disorderRecruitingPhase 32026-10-08NCT07353931
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depressiondepressive disorder, major depressive disorder, mood disorder, psychiatric disorderRecruitingPhase 22026-10-08NCT07300969
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeBody Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arthritic joint disease, arthropathy, musculoskeletal system disorder, nutritional disorder, obesity disorder, osteoarthritis, overnutrition, rheumatic disorderActive, not recruitingPhase 32026-10-08NCT07153471
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 22026-10-08NCT07033494
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trialesophageal adenocarcinomaRecruitingPhase 2 / Phase 32026-10-08NCT06203600
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancerrenal pelvis/ureter urothelial carcinomaRecruitingPhase 2 / Phase 32026-10-08NCT04628767
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerGenital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderRecruitingPhase 32026-10-08NCT03678025
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorderdepressive disorder, major depressive disorder, mood disorder, psychiatric disorderRecruitingPhase 32026-10-07NCT07775300
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)attention deficit hyperactivity disorder, inattentive type, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorderRecruitingPhase 22026-10-07NCT07755410
A Phase 1 Study of Navlimetostat Tablet FormulationsHealthy ParticipantsRecruitingPhase 12026-10-07NCT07544628
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyActive, not recruitingPhase 32026-10-07NCT06653153
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community SettingCrohn disease, Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitisRecruitingPhase 42026-10-07NCT06581328
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-10-07NCT06498635